Skip to main content
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. — Investor Relations & Filings

Ticker · OTLK ISIN · US69012T3059 LEI · 5493007AWUJ6HPMCBH11 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2024-08-14 Regulatory Filings
Country US United States of America
Listing US OTLK

About Outlook Therapeutics, Inc.

https://outlooktherapeutics.com/

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for ophthalmic indications. The company's lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). If approved in the United States, it would be the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. The therapy, under the brand name LYTENAVA™ (bevacizumab gamma), has received Marketing Authorization from the European Commission and the UK's MHRA for the treatment of wet AMD. The monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF).

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2024, reporting the issuance of a press release announcing financial results for the third fiscal quarter ended June 30, 2024. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed filed for certain regulatory purposes. The document is short (3958 characters) and primarily serves as an announcement of the earnings release rather than containing the earnings data itself. According to the rules, such a document is classified as an Earnings Release (ER) if it contains key highlights only, but since this is a Form 8-K announcing the press release and the press release is attached as an exhibit, this is more consistent with a Regulatory Filing (RNS) or possibly an Earnings Release (ER). However, the text states the press release is furnished as an exhibit and the document itself does not contain the financial results, only the announcement. Given the length and content, this is a Regulatory Filing (RNS) reporting the earnings release event rather than the earnings release itself. Therefore, the best classification is Regulatory Filings (RNS).
2024-08-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 8, 2024, by Outlook Therapeutics, Inc. It announces a regulatory event: the granting of Marketing Authorization by the UK MHRA for a product. The content is an announcement of a significant event rather than a detailed financial report or earnings release. The document is relatively short (3833 characters) and primarily serves to inform about a regulatory approval event. There is no financial data, management discussion, or detailed report content. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-08 English
DEF 14A
Proxy Solicitation & Information Statement
2024-06-26 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, as indicated by the header and references to Rule 14a-101 and the Securities Exchange Act of 1934. It is a proxy solicitation document for a special meeting of stockholders of Outlook Therapeutics, Inc. The content includes detailed information about the meeting agenda, voting procedures, and the equity incentive plan proposal. Proxy statements are materials sent to shareholders to provide information and request votes for meetings, which matches the definition of Proxy Solicitation & Information Statement (PSI). The document is lengthy (15,000 characters) and contains substantive information, not just an announcement or a brief notice. Therefore, the correct classification is PSI with high confidence.
2024-06-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 28, 2024. It announces a significant event: the European Commission granting Marketing Authorization for a pharmaceutical product (LYTENAVA) in the EU. The content focuses on the announcement of this regulatory approval event and does not contain financial statements, detailed financial analysis, or management discussion. The document length is 4060 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial results, audit information, or other report types. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-28 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Outlook Therapeutics, Inc. It specifically reports the issuance of a press release announcing financial results for the second fiscal quarter ended March 31, 2024. The text states that the press release is furnished as an exhibit and that the information is not deemed filed for certain regulatory purposes. The document length is 3951 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the full financial results or detailed analysis itself. According to the rules, such a document announcing the initial financial results is classified as an Earnings Release (ER).
2024-05-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.